-
141.发明申请公开(公告)号：US20170081682A1
公开(公告)日：2017-03-23
申请号：US15101097
申请日：2014-12-10
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Arren BAR-EVEN , Ron MILO , Elad NOOR , Lior ZELCBUCH
IPC: C12P7/40 , C12N1/20 , C12N9/10 , C12P7/26 , C12P7/16 , C12P5/02 , C12P5/00 , C12P7/64 , C12N15/52 , C12P7/06
CPC classification number: C12P7/40 , C12N1/20 , C12N9/1029 , C12N15/52 , C12P5/007 , C12P5/023 , C12P5/026 , C12P7/06 , C12P7/16 , C12P7/26 , C12P7/649 , C12Y203/01054 , Y02E50/343
Abstract: An isolated microorganism is disclosed being genetically modified to express pyruvate formate lyase (PFL) or 2-ketobutyrate formate lyase, wherein acetyl-CoA of the microorganism is converted to pyruvate in the presence of formate in a single step reaction, wherein the net flux of the reaction is in the direction of pyruvate synthesis.Uses of the microorganism and products comprising same are also disclosed.
-
142.发明申请Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS 审中-公开减少系统性调节性T细胞水平或治疗CNS疾病和损伤的活动公开(公告)号：US20170029508A1
公开(公告)日：2017-02-02
申请号：US15261945
申请日：2016-09-10
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
Abstract translation: 本说明书公开了一种药物组合物，其包含活性剂，其导致个体中降低全身免疫抑制水平用于治疗CNS的疾病，病症，病状或损伤。 药物组合物通过包含至少一疗程疗程的给药方案施用，每个治疗过程依次包括治疗会话，然后是间歇疗程的非治疗。
-
143.发明申请公开(公告)号：US20170016895A1
公开(公告)日：2017-01-19
申请号：US15108889
申请日：2014-12-31
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Irun R. Cohen , Eytan Domany , Noam Shental , Ittai Fattal
IPC: G01N33/564 , C12Q1/68
Abstract: Methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to specific oligonucleotide antibody reactivities useful in diagnosing SLE in a subject.
Abstract translation: 提供用于诊断受试者系统性红斑狼疮（SLE）的方法和试剂盒。 特别地，本发明涉及可用于诊断受试者中SLE的特异性寡核苷酸抗体反应性。
-
144.发明申请ANTI AMPHIREGULIN ANTIBODIES, COMPOSITIONS COMPRISING SAME AND USES THEREOF 审中-公开抗AMPHIREGULIN抗体，包含其的组合物及其用途公开(公告)号：US20170002068A1
公开(公告)日：2017-01-05
申请号：US15271515
申请日：2016-09-21
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yosef YARDEN , Silvia CARVALHO , Moshit LINDZEN
IPC: C07K16/22 , G01N33/574 , A61K31/704 , A61K45/06 , A61K33/24
CPC classification number: C07K16/22 , A61K31/704 , A61K33/24 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/565 , G01N33/57407 , G01N33/57438 , G01N33/57449 , G01N2333/485 , G01N2333/495 , G01N2800/52
Abstract: A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.
Abstract translation: 本发明提供一种测定受试者用抗双抗调素抗体治疗的适应性的方法，其中所述受试者具有选自卵巢癌，头颈部癌症和表现出抗化学疗法的胰腺癌的癌症。 所述方法包括在生物样品中分析双调蛋白，转化生长因子α（TGF-α）和肝素结合表皮生长因子（HB-EGF）的受试者表达水平，其中所述双调蛋白的表达水平高于预定阈值 并且TGF-α和/或HB-EGF的表达或低于TGF-α和/或HB-EGF的预定水平的表达不表示受试者用抗两性调节蛋白抗体治疗的适合性 。 还提供了治疗癌症的方法，以及抗体和药物组合物。
-
145.发明授权Catalytic processes for obtaining inorganic nanostructures by using soft metals 有权通过使用软金属获得无机纳米结构的催化方法公开(公告)号：US09527735B2
公开(公告)日：2016-12-27
申请号：US14635345
申请日：2015-03-02
Inventor： Reshef Tenne , Olga Brontvein , Jeffrey Gordon , Daniel Feuerman
IPC: H01B1/10 , C01B19/00 , H01B1/08 , C01G39/00 , C01G39/02 , C01G39/06 , C01G41/00 , C01G41/02 , C01B13/32 , C01B13/36 , B82Y30/00 , C10M125/22 , H01B1/06
CPC classification number: C01B19/007 , B82Y30/00 , C01B13/322 , C01B13/366 , C01G39/006 , C01G39/02 , C01G39/06 , C01G41/00 , C01G41/02 , C01P2002/54 , C01P2004/03 , C01P2004/04 , C01P2004/13 , C01P2004/16 , C01P2006/40 , C10M125/22 , C10M2201/065 , C10M2201/066 , H01B1/06 , H01B1/08 , H01B1/10
Abstract: The present invention concerns inorganic nanostructures comprising soft metals at low concentrations and catalytic processes utilizing soft metals for obtaining inorganic nanostructures.
Abstract translation: 本发明涉及包含低浓度的软金属和利用软金属获得无机纳米结构的催化方法的无机纳米结构。
-
Patent Agency Ranking
公开(公告)号：US09526749B2
公开(公告)日：2016-12-27
申请号：US14627593
申请日：2015-02-20
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michael D. Walker , Yoav Soen , Revital Sharivkin
CPC classification number: A61K35/39 , C12N5/0676 , C12N2501/415 , C12N2501/50 , C12N2501/505 , C12N2501/585 , C12N2501/599 , G01N33/56966 , G01N2333/70596 , G01N2333/71 , G01N2500/10
Abstract: Methods of isolating distinct specific cell types within mixed populations of cells. Methods of isolating specific cell types among pancreatic cells, particularly from human islets of Langerhans. Markers and combinations thereof for use in methods of isolating insulin producing islet beta cells for treatment of diabetes.
Abstract translation: 在混合细胞群中分离不同特定细胞类型的方法。 在胰腺细胞，特别是胰岛细胞中分离特异性细胞类型的方法。 用于分离产生胰岛素胰岛β细胞用于治疗糖尿病的方法的标记物及其组合。
-
147.发明申请(BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS 审中-公开（BACTERIO）氯仿荧光素治疗眼病和疾病公开(公告)号：US20160354468A1
公开(公告)日：2016-12-08
申请号：US15240221
申请日：2016-08-18
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Avigdor SCHERZ , Yoram SALOMON , Arie MARCOVICH , Alexander BRANDIS , Daniel WAGNER
IPC: A61K41/00 , A61K31/519 , A61N5/06 , A61K47/18 , A61K9/00 , A61K31/407 , A61K47/36
CPC classification number: A61K41/0071 , A61K9/0048 , A61K31/407 , A61K31/519 , A61K31/555 , A61K47/186 , A61K47/36 , A61N5/062 , A61N2005/0659
Abstract: An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.
Abstract translation: 提供了一种眼用组合物，其包含用于光动力学治疗（PDT）的叶绿素或细菌叶绿素化合物，所述疾病，病症和病症与角膜或巩膜异常相关，例如角膜变薄和巩膜拉伸。
-
148.发明申请ATTENUATION OF ENCRUSTATION OF MEDICAL DEVICES USING COATINGS OF INORGANIC FULLERENE-LIKE NANOPARTICLES 审中-公开使用无机富勒烯类纳米粒子涂层对医疗器械进行加强的衰减公开(公告)号：US20160331874A1
公开(公告)日：2016-11-17
申请号：US15109822
申请日：2015-01-06
Inventor： Reshef TENNE , David ZBAIDA , Racheli RON , Ilan KAFKA , Ilan LEIBOVITZ
CPC classification number: A61L31/088 , A61L29/106 , A61L29/14 , A61L29/18 , A61L31/082 , A61L31/14 , A61L31/18 , A61L2400/12 , A61L2420/02
Abstract: A new approach is presented to reduce encrustation of catheters by the application of nanoparticles. It is demonstrated that the negatively surface charged nanoparticles produce coating films comprised of long-range domains in which the nanoparticles are self-assembled into a mosaic-like order, showing a relatively small tendency to agglomerate.
Abstract translation: 提出了一种新方法，通过应用纳米颗粒来减少导尿管的结垢。 证明负表面带电的纳米颗粒产生包括远距离域的涂膜，其中纳米颗粒自组装成马赛克状的顺序，显示出相对较小的附聚倾向。
-
公开(公告)号：US20160294224A1
公开(公告)日：2016-10-06
申请号：US15177418
申请日：2016-06-09
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yaron SILBERBERG , Haim SUCHOWSKI , Nikolay V. VITANOV , Andon A. RANGELOV
Abstract: A method or apparatus for wireless transferring energy between a source coil and a drain coil, comprises setting an initial resonant frequency of the source coil as a first condition; setting the source coil and said drain coil in positions relative to each other to define an initial coupling coefficient therebetween, so that the initial coupling coefficient comprises a second condition; and adiabatically changing one or both of the conditions while pumping energy into the source coil. The source coil energy is transferred to the drain coil over the course of the adiabatic change.
Abstract translation: 一种用于在源极线圈和漏极线圈之间无线传输能量的方法或装置，包括将源极线圈的初始谐振频率设置为第一条件; 将源极线圈和所述漏极线圈设置在相对于彼此的位置以限定其间的初始耦合系数，使得初始耦合系数包括第二条件; 并绝热地改变一个或两个条件，同时将能量泵入源线圈。 在绝热变化的过程中，源极线圈能量被传递到漏极线圈。
-
公开(公告)号：US20160279169A1
公开(公告)日：2016-09-29
申请号：US15180152
申请日：2016-06-13
Inventor： Daniel OFFEN , Michal DADON-NACHUM , Tali BEN-ZUR , Eldad MELAMED , David YAFFE
CPC classification number: A61K35/34 , A61K35/12 , A61K38/00 , A61K38/185 , A61K38/1866 , A61K38/30 , C12N5/0658 , C12N5/0659 , C12N2501/105 , C12N2501/13 , C12N2501/165 , C12N2510/00
Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
997
records
(took 0.119 seconds)
